Spots Global Cancer Trial Database for degarelix
Every month we try and update this database with for degarelix cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy | NCT00468286 | Prostate Cancer | Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer | NCT05917860 | Localized Prost... Castration-Naiv... Intermediate Ri... Prostate Cancer | Degarelix MRI-guided tran... | 40 Years - 80 Years | Turku University Hospital | |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | NCT03689699 | Prostate Cancer Adenocarcinoma ... | Nivolumab Degarelix BMS-986253 | 18 Years - 99 Years | Columbia University | |
| Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | NCT00818623 | Prostate Cancer | Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer | NCT00833248 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | NCT01377389 | Prostate Cancer | Ipilimumab Leuprolide Goserelin Degarelix | 18 Years - | M.D. Anderson Cancer Center | |
| Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients | NCT01215513 | Prostate Cancer | Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists | NCT02475057 | Prostatic Neopl... Cardiovascular ... | Degarelix (LHRH... LHRH agonist EndoPAT2000 | 18 Years - 90 Years | Rabin Medical Center | |
| Cardiovascular Events in GnRH Agonist vs. Antagonist | NCT04182594 | Hormone Sensiti... Prostate Cancer Cardiac Event | Degarelix GnRH agonist | 18 Years - 90 Years | Rabin Medical Center | |
| Treatment of Prostate Cancer With Firmagon® | NCT01710098 | Prostate Cancer | Degarelix | 18 Years - 95 Years | United Clinic Management GmbH | |
| Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer. | NCT03069937 | Metastatic Pros... | Docetaxel Degarelix | 18 Years - | Medical University of South Carolina | |
| A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer | NCT00116753 | Prostate Cancer | Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | NCT02324998 | Prostate Cancer | Olaparib Degarelix | 18 Years - 73 Years | Cambridge University Hospitals NHS Foundation Trust | |
| Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | NCT03361735 | Prostate Adenoc... | Leuprolide Acet... Goserelin Aceta... Stereotactic Bo... Radium Ra 223 D... Laboratory Biom... Degarelix | 18 Years - | City of Hope Medical Center | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer | NCT06218667 | Prostate Cancer | Copanlisib Degarelix Radical Prostat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer | NCT00116779 | Prostate Cancer | Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data | NCT04897958 | Prostate Cancer | Degarelix Leuprolide | - | Brigham and Women's Hospital | |
| Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. | NCT02234089 | Advanced Prosta... | Degarelix LHRH agonist (L... | - | Ferring Pharmaceuticals | |
| One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population | NCT01744366 | Prostate Cancer | Degarelix Goserelin | 18 Years - | Ferring Pharmaceuticals | |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | NCT01786265 | Prostate Adenoc... Recurrent Prost... | Abiraterone Ace... Bicalutamide Degarelix Flutamide Goserelin Aceta... Leuprolide Acet... Nilutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Degarelix Before Radical Prostatectomy | NCT01852864 | Prostate Cancer | 240mg degarelix... | 18 Years - 80 Years | University of Cambridge | |
| Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy | NCT01994239 | Adenocarcinoma ... | Degarelix Pelvic Radiothe... | 18 Years - | UNICANCER | |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | NCT05873192 | Prostate Cancer | ADT Enzalutamide Talazoparib Degarelix Luprolide | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients | NCT01215513 | Prostate Cancer | Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| ETHAN - ET for Male BC | NCT05501704 | Male Breast Can... Hormone Recepto... Hormone Recepto... | Tamoxifen Anastrozole Degarelix Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data | NCT04897958 | Prostate Cancer | Degarelix Leuprolide | - | Brigham and Women's Hospital | |
| A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer | NCT02526784 | Prostate Cancer | degarelix | 18 Years - | Ferring Pharmaceuticals | |
| A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer | NCT02726009 | Prostate Cancer | Degarelix | 18 Years - 79 Years | Ferring Pharmaceuticals | |
| Safety and Efficacy of Firmagon® (Degarelix) for Injection | NCT02886598 | Prostate Cancer | degarelix | - | Ferring Pharmaceuticals | |
| Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer | NCT02799706 | Prostate Cancer | Degarelix approved GnRH a... Radiotherapy | 18 Years - 80 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | NCT00215657 | Prostate Cancer | Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients | NCT00245466 | Prostate Cancer | Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | NCT02020070 | Metastatic Cast... | Degarelix Ipilimumab Radical Prostat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | NCT02020070 | Metastatic Cast... | Degarelix Ipilimumab Radical Prostat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | NCT05617885 | Metastatic Pros... Non-metastatic ... Prostate Cancer | Darolutamide Abemaciclib GNRH-A Leuproli... GNRH-A Gosereli... Degarelix | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer | NCT01545882 | Prostatic Neopl... | Degarelix | 18 Years - | Ottawa Hospital Research Institute | |
| A Long Term Safety Study of Degarelix in Patients With Prostate Cancer | NCT00967018 | Prostate Cancer | Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer | NCT02468284 | Prostate Cancer | degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC) | NCT01630967 | Prostate Neopla... | Degarelix | 18 Years - | British Columbia Cancer Agency | |
| Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer | NCT02489357 | Stage IV Prosta... | Cryosurgery Degarelix Laboratory Biom... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy | NCT01994239 | Adenocarcinoma ... | Degarelix Pelvic Radiothe... | 18 Years - | UNICANCER | |
| Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | NCT03056638 | Prostate Cancer | Degarelix stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer | NCT02229253 | Advanced Hormon... | degarelix | - | Ferring Pharmaceuticals | |
| Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer | NCT02799706 | Prostate Cancer | Degarelix approved GnRH a... Radiotherapy | 18 Years - 80 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer | NCT04282876 | Bladder Cancer Radiation Thera... Quality of Life | Degarelix | 18 Years - | Aarhus University Hospital | |
| Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy | NCT00468286 | Prostate Cancer | Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer | NCT04176081 | Prostate Cancer | Darolutamide Degarelix Radiation Thera... | 18 Years - | University Health Network, Toronto | |
| Degarelix Neo-Adjuvant Radical Prostatectomy Trial | NCT01674270 | Prostate Cancer | Degarelix Casodex LHRH Agonist | 18 Years - 75 Years | University Health Network, Toronto | |
| A Degarelix Trial in Patients With Prostate Cancer | NCT01242748 | Prostate Cancer | Degarelix Goserelin aceta... | 18 Years - | Ferring Pharmaceuticals | |
| A Study of Degarelix in Taiwanese Patients With Prostate Cancer | NCT01220869 | Prostate Cancer | Degarelix | 20 Years - | Ferring Pharmaceuticals | |
| Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | NCT00215657 | Prostate Cancer | Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | NCT01964170 | Prostate Cancer | degarelix Goserelin | 20 Years - | Astellas Pharma Inc | |
| Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix | NCT03202381 | Prostate Cancer | Degarelix | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Study to Find Maintenance Dose for Periodic Administration of ASP3550 | NCT01261572 | Prostatic Neopl... | degarelix | 20 Years - | Astellas Pharma Inc | |
| Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. | NCT02234089 | Advanced Prosta... | Degarelix LHRH agonist (L... | - | Ferring Pharmaceuticals | |
| Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | NCT00818623 | Prostate Cancer | Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| ETHAN - ET for Male BC | NCT05501704 | Male Breast Can... Hormone Recepto... Hormone Recepto... | Tamoxifen Anastrozole Degarelix Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | NCT02560051 | Prostatic Neopl... | Doxorubicin Ketoconazole Docetaxel Estramustine Degarelix | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | NCT03009981 | Prostate Cancer | Apalutamide LHRH Analogue Abiraterone Ace... Prednisone | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients | NCT00884273 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | NCT02159690 | Prostate Cancer Localized Prost... | Enzalutamide Abiraterone ace... Prednisone Dutasteride Degarelix | 18 Years - | Johns Hopkins University | |
| A Study of Degarelix in Taiwanese Patients With Prostate Cancer | NCT01220869 | Prostate Cancer | Degarelix | 20 Years - | Ferring Pharmaceuticals | |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | NCT03951831 | Prostate Cancer... | REGN2810 Degarelix Leuprolide Acet... Docetaxel | 18 Years - 99 Years | Columbia University | |
| A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | NCT01964170 | Prostate Cancer | degarelix Goserelin | 20 Years - | Astellas Pharma Inc | |
| An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer | NCT02015871 | Prostate Cancer | Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population | NCT01744366 | Prostate Cancer | Degarelix Goserelin | 18 Years - | Ferring Pharmaceuticals | |
| Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | NCT00117312 | Prostate Cancer | Degarelix Degarelix Degarelix Degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Study to Find Maintenance Dose for Periodic Administration of ASP3550 | NCT01261572 | Prostatic Neopl... | degarelix | 20 Years - | Astellas Pharma Inc | |
| ETHAN - ET for Male BC | NCT05501704 | Male Breast Can... Hormone Recepto... Hormone Recepto... | Tamoxifen Anastrozole Degarelix Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | NCT02020070 | Metastatic Cast... | Degarelix Ipilimumab Radical Prostat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | NCT03689699 | Prostate Cancer Adenocarcinoma ... | Nivolumab Degarelix BMS-986253 | 18 Years - 99 Years | Columbia University | |
| Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer | NCT01542021 | Prostate Cancer Prostatic Adeno... | degarelix injec... degarelix injec... androgen depriv... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | NCT03361735 | Prostate Adenoc... | Leuprolide Acet... Goserelin Aceta... Stereotactic Bo... Radium Ra 223 D... Laboratory Biom... Degarelix | 18 Years - | City of Hope Medical Center | |
| Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer | NCT01731912 | Prostate Adenoc... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | Degarelix External Beam R... Laboratory Biom... | 18 Years - | University of Washington | |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | NCT04734730 | Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Bicalutamide Degarelix Goserelin Aceta... Leuprolide Acet... Prednisone Questionnaire A... Talazoparib | 18 Years - | City of Hope Medical Center | |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | NCT04585932 | Biochemically R... Metastatic Pros... Oligometastatic... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Apalutamide Degarelix Leuprolide Acet... Quality-of-Life... Questionnaire A... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
